Insider · CIK 0001749591
Westlake BioPartners Fund I, L.P.
Files at KYTX (Kyverna Therapeutics, Inc.), LTGO (Latigo Biotherapeutics, Inc.). First filing -, latest -.
In brief
Westlake BioPartners Fund I, L.P. files SEC Form 4 as 10% owner at KYTX (Kyverna Therapeutics, Inc.), and also at LTGO (Latigo Biotherapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Westlake BioPartners Fund I, L.P. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +938,979 | - | - | 1,368,532 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +3,547,842 | - | - | 4,916,374 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +1,027,635 | - | - | 5,944,009 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +3,464,072 | - | - | 3,510,927 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +1,484,401 | - | - | 4,995,328 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +165,519 | - | - | 5,160,847 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See footnote | +2,066,857 | - | - | 2,094,813 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series Seed Convertible Preferred Stockderivativeindirect: See footnote | -938,979 | - | - | 0 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -3,547,842 | - | - | 0 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -1,027,635 | - | - | 0 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -3,464,072 | - | - | 0 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -1,484,401 | - | - | 0 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -2,066,857 | - | - | 0 | Aug 11, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Convertible Promissory Notederivativeindirect: See footnote | -165,519 | - | - | 0 | Aug 11, 2026 |
Questions about Westlake BioPartners Fund I, L.P.
Answered from the filings on this page, as of the latest one.
Is Westlake BioPartners Fund I, L.P. buying or selling?
Westlake BioPartners Fund I, L.P. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Westlake BioPartners Fund I, L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Westlake BioPartners Fund I, L.P. has 0.
Where does Westlake BioPartners Fund I, L.P. file Form 4?
Westlake BioPartners Fund I, L.P. has filed Form 4 at KYTX (Kyverna Therapeutics, Inc.); LTGO (Latigo Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.